Get the Stockscreener App
9.19
3.35%
-0.36
Champions Oncology Inc stock is traded at $9.19, with a volume of 25,875.
It is down -3.35% in the last 24 hours and down -16.55% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$9.55
Open:
$9.44
24h Volume:
25,875
Relative Volume:
0.42
Market Cap:
$124.80M
Revenue:
$49.98M
Net Income/Loss:
$-9.64M
P/E Ratio:
-12.94
EPS:
-0.71
Net Cash Flow:
$-4.86M
1W Performance:
-7.79%
1M Performance:
-16.55%
6M Performance:
+82.77%
1Y Performance:
+67.82%
1-Day Range:
$8.73
$9.45
1-Week Range:
$8.601
$10.18
52-Week Range:
$3.6001
$11.99
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
9.10 | 124.80M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.00 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.85 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.15 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.25 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.38 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
Champions Oncology Third Quarter 2025 Earnings: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024) - Yahoo Finance
Champions Oncology target raised to $12 at Craig-Hallum By Investing.com - Investing.com Canada
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2025 Earnings Call Transcript - Insider Monkey
Champions Oncology Achieves Record Revenue and Profit - TipRanks
Champions Oncology earnings beat by $0.37, revenue topped estimates - Investing.com Canada
Earnings call transcript: Champions Oncology Q1 2025 earnings beat expectations By Investing.com - Investing.com UK
CHAMPIONS ONCOLOGY Earnings Results: $CSBR Reports Quarterly Earnings - Nasdaq
Champions Oncology stock surges as earnings beat expectations - Investing.com India
Champions Oncology Reports Record Quarterly Revenue and Net Income - TradingView
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million - ACCESS Newswire
Stock Index Futures Gain After Yesterday’s Selloff, U.S. JOLTs Report in Focus - TradingView
Earnings Scheduled For March 11, 2025 - Benzinga
CHAMPIONS ONCOLOGY Earnings Preview: Recent $CSBR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Champions Oncology Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025 - ACCESS Newswire
When Will Champions Oncology Report Q3 Results? Key Date for Oncology Research Leader - StockTitan
(CSBR) Technical Pivots with Risk Controls - Stock Traders Daily
Targeted Oncology Adds The Florida Society of Clinical Oncology to Its Strategic Alliance Partnership Program - Florida Trend
CSBR stock hits 52-week high at $10.91 amid robust growth - MSN
We're Interested To See How Champions Oncology (NASDAQ:CSBR) Uses Its Cash Hoard To Grow - Yahoo Finance
Champions Oncology Reports Quarterly Revenue of $6.7 Million - ACCESS Newswire
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023 - ACCESS Newswire
ZERO Advocacy Summit Ignites National Movement for Prostate Cancer Reform, Rallying Patients, Survivors, and Policymakers on Capitol Hill - Yahoo Finance
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million - ACCESS Newswire
Champions Oncology, Inc. to Host Earnings Call - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $7.6 Million - ACCESS Newswire
Champions Oncology Reports Record Quarterly Revenue of $11.3 Million - ACCESS Newswire
Champions Oncology (NASDAQ:CSBR) pulls back 16% this week, but still delivers shareholders notable 57% return over 1 year - Simply Wall St
CSBRChampions Oncolo Latest Stock News & Market Updates - StockTitan
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022 - ACCESS Newswire
Champions Oncology Reports Record Quarterly Revenue of $10.8 Million - ACCESS Newswire
Prospect High students champions in fight against blood cancer - Daily Herald
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 11, 2021 - ACCESS Newswire
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting - ACCESS Newswire
Revolutionary Cancer Research Alert: Champions Oncology Unveils 17 Game-Changing Studies at AACR 2025 - StockTitan
Flow Cytometry Market Size to Worth USD 12.11 Billion by 2034 - GlobeNewswire
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024 - ACCESS Newswire
(CSBR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Champions Oncology Reports Record Quarterly Revenue of $14.3 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $13.1 Million - ACCESS Newswire
Champions Oncology to Announce Fourth Quarter Financial Results on Monday, July 15, 2019 - ACCESS Newswire
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024 - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.9 Million - ACCESS Newswire
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2020 - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million - ACCESS Newswire
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics - ACCESS Newswire
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024 - ACCESS Newswire
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification - ACCESS Newswire
Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations - ACCESS Newswire
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):